Peptides for Longevity in Australia: Research Guide

The short answer

There is no peptide approved in Australia as an anti-ageing medicine, and no compound discussed on this page is a registered therapeutic good for that purpose. The phrase peptides for longevity describes a loose research category, meaning compounds that scientists have studied in the context of ageing biology and cellular health. It does not describe a treatment, a protocol, or a proven outcome.

Most of the compounds covered here are studied in laboratory and animal models, with only limited early human data for a few. In Australia they are generally not on the Australian Register of Therapeutic Goods (ARTG) and are commonly supplied as research chemicals for in vitro investigation, not for human administration.

What longevity peptides means as a research category

Ageing research has identified several biological processes that change over time, sometimes called the hallmarks of ageing. These include telomere shortening, declining mitochondrial function, falling levels of the cofactor NAD+, and changes in tissue repair. Longevity peptides is an informal umbrella term for peptides and small molecules that researchers have examined in relation to one or more of these processes.

It is important to read the term carefully. Grouping compounds under a research heading does not mean they share a mechanism, a quality of evidence, or any demonstrated effect in people. Each compound sits at a different point on the research path, and for most of them the human evidence is early or absent.

Epithalon (epitalon)

Epithalon, also written epitalon, is a synthetic four amino acid peptide (the sequence alanine, glutamic acid, aspartic acid, glycine) based on a substance associated with the pineal gland. In research settings it has been studied for its reported effects on gene expression and on telomere related pathways in cell and animal models.

The evidence base is largely preclinical and a good portion of it is older. There are no robust, modern, large scale human randomised trials establishing an effect on ageing. Researchers treat epithalon as an investigational compound, and its laboratory findings do not translate into claims about people.

MOTS-c

MOTS-c is a mitochondrial derived peptide, meaning it is encoded within mitochondrial DNA. Because mitochondrial decline is one recognised feature of ageing, MOTS-c has been studied in relation to metabolic function, insulin sensitivity, and cellular stress responses, mostly in cell culture and animal models.

MOTS-c is at an earlier translational stage than many approved medicines. Most published work is preclinical, with limited early human investigation into metabolic markers. It is studied as a research compound, and the available data do not support conclusions about human ageing or health.

NAD+ precursors: NMN and NR

NAD+ (nicotinamide adenine dinucleotide) is a cellular cofactor whose levels tend to decline with age. Two precursor molecules, nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), have been studied for their ability to raise NAD+ related metabolites. Note that these are small molecules rather than peptides, but they often appear in the same longevity research conversation.

Their Australian regulatory position differs from the peptides above. Nicotinamide riboside has been available in listed medicines in Australia for several years. For NMN, the TGA added the ingredient to its permissible ingredients determination in December 2025, with specific conditions on sponsorship and oral use, which changed its availability as a listed ingredient. Early human studies suggest NMN and NR can raise NAD+ metabolites over time, but long term benefits and risks in people are not established.

GHK-Cu and other studied compounds

GHK-Cu is a copper binding tripeptide with a long history in cell culture, animal, and topical cosmetic research, where it has been examined for roles in collagen synthesis, wound related processes, and gene expression. Cell and animal observations, however, do not establish human clinical outcomes, and large modern trials are limited.

Other compounds sometimes grouped into ageing research include Humanin, another mitochondrial derived peptide studied in cellular models, and SS-31 (also called elamipretide), a mitochondria targeting peptide that has been investigated in some clinical research programs for specific conditions rather than for ageing in general. In all cases the honest summary is the same: interesting laboratory signals, limited human data, and no approval as an anti-ageing medicine in Australia.

Where the evidence typically sits

• Epithalon: mostly preclinical, older literature, no robust modern human ageing trials
• MOTS-c: largely preclinical with limited early human metabolic study
• NMN and NR: early human data on NAD+ metabolites; long term outcomes unestablished
• GHK-Cu: extensive cell, animal and topical research; limited modern clinical trials
• Humanin and SS-31: cellular and clinical research in specific areas, not ageing claims

The Australian regulatory reality

In Australia, therapeutic goods are regulated under the Therapeutic Goods Act 1989. Two separate systems matter here. The Poisons Standard sorts substances into schedules that control access, while the ARTG lists products that have been assessed and approved for supply. A substance can be scheduled without being on the ARTG, because the two answer different questions.

Many research peptides are captured as Schedule 4 (Prescription Only Medicine) substances, and the TGA has, over recent years, scheduled or clarified the status of a range of peptides. Crucially, the great majority of research peptide products sold online are not on the ARTG, so they are not approved medicines. None of the compounds in this article is approved by the TGA as an anti-ageing treatment.

Research-grade supply versus an approved medicine

An approved medicine on the ARTG has been assessed for quality, safety, and the claims made about it, and it is manufactured under regulated conditions with a defined therapeutic indication. A research chemical sold for in vitro use carries no such approval. It is not evaluated for human use, it has no approved indication, and it should not be treated as interchangeable with a registered product.

For researchers sourcing reference material, this distinction shapes what quality information is reasonable to request. A Certificate of Analysis (CoA) can report identity and purity for a given batch, typically using methods such as high performance liquid chromatography (HPLC) and mass spectrometry. A CoA describes what is in a vial for laboratory purposes; it is not an approval, a safety assessment, or permission for human use.

Quality and documentation points for research buyers

• Look for a batch specific CoA rather than a generic one
• Check which analytical methods were used for identity and purity
• Confirm the compound and batch number match the documentation
• Understand that purity data does not imply safety or efficacy in humans
• Remember that research use only status is a legal and practical boundary, not marketing language